G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by HC Wainwright

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 100.45% from the company’s previous close. HC Wainwright also issued estimates for G1 Therapeutics’ FY2026 earnings at $0.72 EPS.

GTHX has been the subject of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of G1 Therapeutics in a research note on Wednesday. Wedbush restated an “outperform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th.

G1 Therapeutics Price Performance

NASDAQ:GTHX traded up $0.05 on Thursday, reaching $4.49. The stock had a trading volume of 574,426 shares, compared to its average volume of 665,254. The company has a quick ratio of 3.45, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $234.74 million, a P/E ratio of -7.24 and a beta of 1.71. G1 Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.00. The stock has a fifty day moving average price of $3.90 and a 200-day moving average price of $3.06.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, May 1st. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The business had revenue of $14.48 million during the quarter, compared to analyst estimates of $15.21 million. During the same period in the previous year, the firm earned ($0.53) earnings per share. Research analysts forecast that G1 Therapeutics will post -0.64 EPS for the current year.

Insider Buying and Selling

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at approximately $785,113.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On G1 Therapeutics

Several hedge funds have recently added to or reduced their stakes in GTHX. Financial Advocates Investment Management bought a new stake in shares of G1 Therapeutics in the 4th quarter valued at about $39,000. Capstone Investment Advisors LLC acquired a new position in G1 Therapeutics during the fourth quarter valued at approximately $76,000. Algert Global LLC bought a new stake in G1 Therapeutics in the third quarter valued at approximately $98,000. Curi Wealth Management LLC raised its holdings in G1 Therapeutics by 17.8% in the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock worth $102,000 after purchasing an additional 10,700 shares during the period. Finally, Jump Financial LLC acquired a new stake in G1 Therapeutics in the fourth quarter worth $105,000. Institutional investors and hedge funds own 24.21% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.